curasan AG reported earnings results for the first quarter of fiscal year 2016. For the quarter, the company reported adjusted gross revenues increased by 2.5% to EUR 1.63 million compared to the same period in 2015. The reason for the repeated adjustment in gross revenues is the cessation of sales activities for the unprofitable product Cytoplast. Final revenues of EUR 0.13 million resulted from the sale of the remaining inventories in the first quarter of 2015. The result before taxes, interest, depreciation and amortization (EBITDA) decreased to negative EUR 0.33 million from negative EBITDA of EUR 0.07 million in the previous year. This was due on the one hand to a non-recurring effect from currency translation gains amounting to EUR 0.13 million resulting from the debt consolidation from the American subsidiary curasan inc. in the comparable period of the previous year. On the other hand, personnel costs rose as planned in line with the growth strategy. Operative cash out flow at EUR 0.88 million was significantly below the figure of EUR 0.43 million for the previous year. The difference, which was larger than planned, is largely due to accruals-based accounting.